Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression.
Company Details
- Employees
- 54
- Founded
- -
- Address
- San Diego, Ca, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.contineum-tx.com/
- HQ
- San Diego, CA
Contineum Therapeutics Questions
Contineum Therapeutics's website is https://www.contineum-tx.com/
Contineum Therapeutics's LinkedIn profile is https://www.linkedin.com/company/contineumtherapeutics
Contineum Therapeutics has
54 employees.
View email and phone details for 54
employees at Contineum Therapeutics.
Contineum Therapeutics's industry is
Pharmaceutical Manufacturing
Contineum Therapeutics's top competitors are
Obsidian Therapeutics,
Autobahn Therapeutics, Inc.,
Diagonal Therapeutics,
Rapport Therapeutics,
Avidity Biosciences, Inc.,
Neurocrine Biosciences,
Artiva Biotherapeutics,
Vividion Therapeutics, Inc.,
Denali Therapeutics,
Alterome Therapeutics, Inc.
Contineum Therapeutics's categories are Pharmaceutical Manufacturing
Contineum Therapeutics's founding year is 2017
